AltaRex Report issue

For profit Phase 2
Founded: Edmonton AB Canada (1999)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1998

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

oregovomab (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1